Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponsegromab versus placebo with first-line chemotherapy in metastatic pancreatic ductal adenocarcinoma cachexia
2025-522093-36-00Phase 3Suspended
- Sponsor
- Pfizer
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in cancer anorexia-cachexia syndrome (CACS) comparing Ponsegromab + background chemotherapy with Placebo + background chemotherapy (2 arms). Started May 2026; status: suspended.
02
Drugs
ponsegromab
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on 2025-522093-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522093-36-00.